LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.33 3.1

Buy Sell

Overview

Share price change

24h

Current

Min

1.33

Max

1.34

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+50.38% upside

Dividends
By Dow Jones
Next Earnings	12 mar 2026

Market Stats
By TradingEconomics
Market Cap	-24M 78M
Previous open	-1.77
Previous close	1.33

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 mar 2026, 19:32 UTC

Acquisitions, Mergers, Takeovers

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

7 mar 2026, 02:30 UTC

Major News Events

Iran War Is Kicking India When It's Already Down -- Barrons.com

6 mar 2026, 22:26 UTC

Major News Events

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Earnings

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Major News Events

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Earnings

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Earnings

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Earnings

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Major News Events

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Market Talk

Major News Events

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Market Talk

Major News Events

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mar 2026, 17:46 UTC

Major News Events

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mar 2026, 17:40 UTC

Market Talk

Earnings

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mar 2026, 17:40 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 17:32 UTC

Market Talk

Major News Events

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mar 2026, 17:28 UTC

Market Talk

Major News Events

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mar 2026, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

6 mar 2026, 17:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

50.38% upside

12 Months Forecast

Average 2 USD 50.38%

High 2 USD

Low 2 USD

Based on 1 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.